Sherry Shen, MD's Avatar

Sherry Shen, MD

@sherryshenmd.bsky.social

Breast med onc & researcher at MSKCC, Co-Director of the MSK Lobular Breast Cancer Program, Columbia Med & UMich alum

84 Followers  |  42 Following  |  6 Posts  |  Joined: 27.11.2024  |  1.5515

Latest posts by sherryshenmd.bsky.social on Bluesky

A big thank you to Dr. Mouabbi @jamouabbi.bsky.social
and Dr. Shen @sherryshenmd.bsky.social for your time and wonderful presentations on lobular cancer. Thank you
@graspcancer.bsky.social for organizing these sessions!

11.06.2025 15:36 — 👍 1    🔁 1    💬 0    📌 0

So great meeting you! Let’s connect again soon :)

27.04.2025 10:28 — 👍 1    🔁 0    💬 0    📌 0

Thank you @theaacr.bsky.social for inviting me to speak on integrating GLP-1RAs into clinical cancer care. Great session alongside Drs. Stephen Hursting & Rong Xu. Some data on use in cancer patients now, but so much more needed!

27.04.2025 10:25 — 👍 7    🔁 2    💬 0    📌 0
Post image

At #AACR25, join breast medical oncologist @sherryshenmd.bsky.social for an education session on best practices to introduce GLP1-RAs, like Ozempic, into clinical #cancer care. @mskcancercenter.bsky.social @theaacr.bsky.social Learn more: bit.ly/4jso7Ed

3:01-3:21 p.m. CT

26.04.2025 18:30 — 👍 4    🔁 2    💬 0    📌 0

Congrats!

18.12.2024 16:36 — 👍 1    🔁 0    💬 0    📌 0
Post image Post image Post image Post image

Wrapping up another fantastic #SABCS!

Amazing, practice-changing data were presented.

I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!

#SABCS24 @oncoalert.bsky.social

13.12.2024 20:08 — 👍 45    🔁 19    💬 0    📌 3

Thanks Sarah! While we didn’t compare lobular vs. ductal, mPFS in our cohort was similar to other real-world cohorts of predominantly IDC patients.

13.12.2024 14:48 — 👍 0    🔁 0    💬 0    📌 0
Post image

When @breastcancerdoc.bsky.social & I are unintentionally matching at our poster on T-DXd in pts with HER2-low lobular MBC. PFS 7.2m in total cohort, shorter in those with PIK3CA/AKT/PTEN muts & trend toward longer in HER2mut. More research needed in lobular BC!

13.12.2024 14:09 — 👍 11    🔁 4    💬 2    📌 1
Post image Post image Post image Post image

First Bluesky post! EMBER-3 presented by my mentor @breastcancerdoc.bsky.social demonstrating greater mPFS as single agent vs. SOC ET in ESR1mut, and impressive benefit of imlunestrant+abema with mPFS 9.4 months, 59% had prior CDK4/6i. Novel ET + CDK4/6i switch is intriguing - ELAINE3 is enrolling!

11.12.2024 16:21 — 👍 4    🔁 2    💬 0    📌 0

@sherryshenmd is following 19 prominent accounts